{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:38:29Z","timestamp":1775695109166,"version":"3.50.1"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Harmonics European Union Project","award":["ID: 731944"],"award-info":[{"award-number":["ID: 731944"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jaut.2019.102317","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T17:35:04Z","timestamp":1566322504000},"page":"102317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Genetic contributors and soluble mediators in prediction of autoimmune comorbidity"],"prefix":"10.1016","volume":"104","author":[{"given":"Adrianos","family":"Nezos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Eleutheria","family":"Evangelopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clio P.","family":"Mavragani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2019.102317_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/acr.23015","article-title":"Comorbidities in patients with primary sjogren's syndrome and systemic lupus erythematosus: a comparative registries-based study","volume":"69","author":"Rua-Figueroa","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2019.102317_bib2","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jaut.2019.102317_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaut.2012.01.002","article-title":"Pathogenesis of Sjogren's syndrome: what we know and what we should learn","volume":"39","author":"Tzioufas","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102317_bib4","article-title":"Lymphomas complicating primary Sjogren\u2019s syndrome: from autoimmunity to lymphoma","author":"Nocturne","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102317_bib5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2019.00312","article-title":"Fatigue in sjogren's syndrome: a search for biomarkers and treatment targets","volume":"10","author":"Bodewes","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2019.102317_bib6","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/rheumatology\/keq158","article-title":"Psychopathological and personality features in primary Sjogren's syndrome--associations with autoantibodies to neuropeptides","volume":"49","author":"Karaiskos","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102317_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-019-04354-0","article-title":"Fatigue in primary Sjogren\u2019s syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study","author":"Davies","year":"2019","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jaut.2019.102317_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0002-9343(76)90431-9","article-title":"The bimodal mortality pattern of systemic lupus erythematosus","volume":"60","author":"Urowitz","year":"1976","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jaut.2019.102317_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncpcardio0270","article-title":"Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease","volume":"2","author":"Haque","year":"2005","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"10.1016\/j.jaut.2019.102317_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fpsyt.2018.00246","article-title":"Anxiety and extraversion in lupus-related atherosclerosis","volume":"9","author":"Giannelou","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jaut.2019.102317_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.05.008","article-title":"Cardiovascular disease in systemic lupus erythematosus: a comprehensive update","volume":"82","author":"Giannelou","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102317_bib12","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1002\/art.21475","article-title":"Precocious intima-media thickening in patients with primary Sjogren's syndrome","volume":"52","author":"Vaudo","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-015-0613-6","article-title":"Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations","volume":"17","author":"Gravani","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102317_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3389\/fimmu.2019.00817","article-title":"Subclinical atherosclerosis in primary sjogren's syndrome: does inflammation matter?","volume":"10","author":"Bartoloni","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2019.102317_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10067-018-4265-1","article-title":"Association between primary Sjogren's syndrome, arterial stiffness, and subclinical atherosclerosis: a systematic review and meta-analysis","volume":"38","author":"Yong","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102317_bib16","first-page":"361","article-title":"New parameters for identifying subclinical atherosclerosis in patients with primary Sjogren's syndrome: a pilot study","volume":"32","author":"Atzeni","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Suppl 112","key":"10.1016\/j.jaut.2019.102317_bib17","first-page":"68","article-title":"Psychological comorbidities associated with subclinical atherosclerosis in Greek patients with primary Sjogren's syndrome: a potential contribution of sleep impairment","volume":"36","author":"Karageorgas","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102317_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11926-019-0842-9","article-title":"Innate immune dysregulation in the development of cardiovascular disease in lupus","volume":"21","author":"Tumurkhuu","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2019.102317_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaut.2007.02.004","article-title":"The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia","volume":"28","author":"Hahn","year":"2007","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102317_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029371","article-title":"Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation","volume":"7","author":"Kyaw","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102317_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/1744666X.2019.1571411","article-title":"B cells and atherosclerosis in systemic lupus erythematosus","volume":"15","author":"Koulouri","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2019.102317_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.autrev.2007.06.003","article-title":"OxLDL\/beta2GPI-anti-oxLDL\/beta2GPI complex and atherosclerosis in SLE patients","volume":"7","author":"Bassi","year":"2007","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2019.102317_bib23","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1161\/01.CIR.0000143225.07377.EA","article-title":"Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?","volume":"110","author":"Shoenfeld","year":"2004","journal-title":"Circulation"},{"issue":"Suppl 112","key":"10.1016\/j.jaut.2019.102317_bib24","first-page":"61","article-title":"Autoantibodies to ox-LDL in Sjogren's syndrome: are they atheroprotective?","volume":"36","author":"Cinoku","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102317_bib25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","article-title":"Overexpression of the cytokine BAFF and autoimmunity risk","volume":"376","author":"Steri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102317_bib26","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/nm.3284","article-title":"B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction","volume":"19","author":"Zouggari","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2019.102317_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jaut.2018.05.002","article-title":"B-cell activating factor and related genetic variants in lupus related atherosclerosis","volume":"92","author":"Theodorou","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102317_bib28","doi-asserted-by":"crossref","first-page":"A70","DOI":"10.1136\/annrheumdis-2016-211054.9","article-title":"Influence of B-cell activating factor genetic variants in Sj\u00f6gren\u2019s syndrome related atherosclerosis","volume":"76","author":"Karageorgas","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib29","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1158\/0008-5472.CAN-08-4915","article-title":"Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma","volume":"69","author":"Novak","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jaut.2019.102317_bib30","first-page":"289","article-title":"B-cell activating factor promoter polymorphisms in egyptian patients with systemic lupus erythematosus","volume":"43","author":"Zayed","year":"2013","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.jaut.2019.102317_bib31","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1002\/art.22924","article-title":"Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus","volume":"56","author":"Roman","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11883-006-0046-4","article-title":"Homocysteine: role and implications in atherosclerosis","volume":"8","author":"Guthikonda","year":"2006","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.jaut.2019.102317_bib33","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/CIRCULATIONAHA.114.013311","article-title":"Homocysteine and MTHFR mutations","volume":"132","author":"Moll","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jaut.2019.102317_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2018.02.014","article-title":"Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis","volume":"193","author":"Giannelou","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jaut.2019.102317_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/CIRCGENETICS.113.000044","article-title":"Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants","volume":"6","author":"Leonard","year":"2013","journal-title":"Circulation Cardiovascular genetics"},{"key":"10.1016\/j.jaut.2019.102317_bib36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa033122","article-title":"Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus","volume":"351","author":"Ohlenschlaeger","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102317_bib37","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2009.115535","article-title":"A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus","volume":"69","author":"Svenungsson","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib38","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1136\/annrheumdis-2017-212614","article-title":"Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis","volume":"77","author":"Leonard","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/jth.14385","article-title":"Human low-affinity IgG receptor FcgammaRIIA polymorphism H131R associates with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus","volume":"17","author":"Clancy","year":"2019","journal-title":"J. Thromb. Haemost. : JTH"},{"key":"10.1016\/j.jaut.2019.102317_bib40","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2019-eular.5457","article-title":"Parathormone but not vitamin D serum levels are associated with subclinical atherosclerosis in patients with systemic lupus erythematosus \u2005Annals of the","volume":"78","author":"Giannelou","year":"2019","journal-title":"Rheumatic Diseases"},{"key":"10.1016\/j.jaut.2019.102317_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13075-018-1805-7","article-title":"Common mechanisms and holistic care in atherosclerosis and osteoporosis","volume":"21","author":"Szekanecz","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102317_bib42","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13075-015-0595-4","article-title":"Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study","volume":"17","author":"Ajeganova","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102317_bib43","article-title":"Decreased bone mineral density is an independent predictor for the development of atherosclerosis: a systematic review and meta-analysis","volume":"11","author":"Ye","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102317_bib44","article-title":"Osteoporosis and vascular calcification: a shared scenario","author":"Garcia-Gomez","year":"2019","journal-title":"Cl\u00edn. Invest. Arterioscler.\u202f: Publicacion Oficial de La Sociedad Espanola de Arteriosclerosis"},{"key":"10.1016\/j.jaut.2019.102317_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/0961203317751060","article-title":"Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls","author":"Poornima","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2019.102317_bib46","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0961203316682101","article-title":"Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus","volume":"26","author":"Kiani","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2019.102317_bib47","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/CIRCULATIONAHA.113.002654","article-title":"Role of vitamin D in atherosclerosis","volume":"128","author":"Kassi","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jaut.2019.102317_bib48","doi-asserted-by":"crossref","DOI":"10.7326\/M19-0341","article-title":"Effects of nutritional supplements and dietary interventions on cardiovascular outcomes: an umbrella review and evidence map","author":"Khan","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2019.102317_bib49","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1210\/jc.2012-3038","article-title":"Plasma Dickkopf1 (DKK1) concentrations negatively associate with atherosclerotic calcified plaque in African-Americans with type 2 diabetes","volume":"98","author":"Register","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jaut.2019.102317_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199504","article-title":"Circulating levels of sclerostin are associated with cardiovascular mortality","volume":"13","author":"Novo-Rodriguez","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102317_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.coph.2018.04.011","article-title":"Targeting WNT signaling in the treatment of osteoporosis","volume":"40","author":"Baron","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jaut.2019.102317_bib52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13075-017-1352-7","article-title":"High-sensitivity cardiac troponin T is a biomarker for atherosclerosis in systemic lupus erythematous patients: a cross-sectional controlled study","volume":"19","author":"Divard","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102317_bib53","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/0003319715616240","article-title":"Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus","volume":"67","author":"Icli","year":"2016","journal-title":"Angiology"},{"key":"10.1016\/j.jaut.2019.102317_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.01.022","article-title":"Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis","volume":"270","author":"Wigren","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jaut.2019.102317_bib55","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/art.27392","article-title":"Relationship of asymmetric dimethylarginine and homocysteine to vascular aging in systemic lupus erythematosus patients","volume":"62","author":"Perna","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib56","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/art.38204","article-title":"A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus","volume":"66","author":"McMahon","year":"2014","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102317_bib57","doi-asserted-by":"crossref","first-page":"452","DOI":"10.21037\/atm.2018.11.04","article-title":"Elevation of serum proprotein convertase subtilisin\/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus","volume":"6","author":"Fang","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jaut.2019.102317_bib58","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/art.24677","article-title":"Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus","volume":"60","author":"McMahon","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000255","volume":"5","author":"Gupta","year":"2018","journal-title":"Lupus science & medicine"},{"key":"10.1016\/j.jaut.2019.102317_bib60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.leukres.2018.11.004","article-title":"Systemic lupus erythematosus and lymphoma: incidence, pathogenesis and biology","volume":"75","author":"Klein","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jaut.2019.102317_bib61","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib62","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11926-003-0011-y","article-title":"Lymphoproliferation in autoimmunity and Sjogren's syndrome","volume":"5","author":"Voulgarelis","year":"2003","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2019.102317_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.01.001","article-title":"Sjogren's syndrome: a forty-year scientific journey","volume":"51","author":"Moutsopoulos","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102317_bib64","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0002-9343(64)90101-9","article-title":"The development of malignant lymphoma in the course of sjoegren's syndrome","volume":"36","author":"Talal","year":"1964","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jaut.2019.102317_bib65","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","article-title":"Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome","volume":"29","author":"Skopouli","year":"2000","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib66","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003766","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.jaut.2019.102317_bib67","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3899\/jrheum.180101","article-title":"Tongue atrophy in sjogren syndrome patients with mucosa-associated lymphoid tissue lymphoma: autoimmune epithelitis beyond the epithelial cells of salivary glands?","volume":"45","author":"Zampeli","year":"2018","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102317_bib68","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary sjogren's syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102317_bib69","first-page":"272","article-title":"Overlap of ACA-positive systemic sclerosis and Sjogren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma","volume":"31","author":"Baldini","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102317_bib70","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib71","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.1780390508","article-title":"Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome","volume":"39","author":"Tzioufas","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059868","article-title":"Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort","volume":"8","author":"Gottenberg","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102317_bib73","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2013-204634","article-title":"The prognostic value of routinely performed minor salivary gland assessments in primary Sjogren's syndrome","volume":"73","author":"Risselada","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib74","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib75","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1191\/096120398678920019","article-title":"Young onset of primary Sjogren's syndrome: clinical and immunological characteristics","volume":"7","author":"Ramos-Casals","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2019.102317_bib76","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1002\/art.39231","article-title":"A BAFF receptor His159Tyr mutation in Sjogren's syndrome-related lymphoproliferation","volume":"67","author":"Papageorgiou","year":"2015","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102317_bib77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jaut.2019.102317_bib78","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.critrevonc.2014.02.004","article-title":"Role of BAFF\/BAFF-R axis in B-cell non-Hodgkin lymphoma","volume":"91","author":"Yang","year":"2014","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"10.1016\/j.jaut.2019.102317_bib79","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","article-title":"BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands","volume":"52","author":"Quartuccio","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102317_bib80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102317_bib81","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1002\/art.27611","article-title":"The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjogren's syndrome","volume":"62","author":"Tobon","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib82","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1002\/art.38129","article-title":"Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren's syndrome","volume":"65","author":"Tobon","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib83","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.39315","article-title":"CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary sjogren's syndrome","volume":"67","author":"Nocturne","year":"2015","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102317_bib84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaut.2013.04.005","article-title":"B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome","volume":"51","author":"Nezos","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102317_bib85","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2326-6066.CIR-18-0698","article-title":"IL1R8 deficiency drives autoimmunity-associated lymphoma development","volume":"7","author":"Riva","year":"2019","journal-title":"Cancer immunology research"},{"key":"10.1016\/j.jaut.2019.102317_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1573395511309010003","article-title":"Possible mechanisms of lymphoma development in sjogren's syndrome","volume":"9","author":"Dong","year":"2013","journal-title":"Curr. Immunol. Rev."},{"key":"10.1016\/j.jaut.2019.102317_bib87","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.V96.2.410.014k22_410_419","article-title":"The gastric marginal zone B-cell lymphoma of MALT type","volume":"96","author":"Zucca","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2019.102317_bib88","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nrgastro.2010.58","article-title":"Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development","volume":"7","author":"Sagaert","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2019.102317_bib89","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/art.23073","volume":"56","author":"Manoussakis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib90","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jaut.2018.02.010","article-title":"Systemic activation of NLRP3 inflammasome in patients with severe primary Sjogren's syndrome fueled by inflammagenic DNA accumulations","volume":"91","author":"Vakrakou","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102317_bib91","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1194\/jlr.R024190","article-title":"Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2","volume":"53","author":"Rosenson","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jaut.2019.102317_bib92","series-title":"Keizo Inoue DMS, Fuyuhiko Tamanoi","first-page":"157","article-title":"Chapter ten - diverse functions of plasma PAF-AH in tumorigenesis","author":"Stafforini","year":"2015"},{"key":"10.1016\/j.jaut.2019.102317_bib93","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1158\/1535-7163.MCT-05-0146","article-title":"Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures","volume":"4","author":"Mahadevan","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jaut.2019.102317_bib94","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2019-eular.5758","article-title":"The role pf the phospholipase LP-PLA2 activity in Sjogren's syndrome realted lymphomagenesis: a new serum biomarker?","volume":"78","author":"Kotsifaki","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib95","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fimmu.2018.00104","article-title":"A20\/Tumor necrosis factor alpha-induced protein 3 in immune cells controls development of autoinflammation and autoimmunity: lessons from mouse models","volume":"9","author":"Das","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2019.102317_bib96","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/ncb3609","article-title":"A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation of Snail1","volume":"19","author":"Lee","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jaut.2019.102317_bib97","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12026-015-8677-6","article-title":"Roles of A20 in autoimmune diseases","volume":"64","author":"Zhang","year":"2016","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jaut.2019.102317_bib98","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1182\/blood-2013-05-503383","article-title":"Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome","volume":"122","author":"Nocturne","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2019.102317_bib99","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2015-207731","article-title":"Germline variation of TNFAIP3 in primary Sjogren's syndrome-associated lymphoma","volume":"75","author":"Nocturne","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib100","doi-asserted-by":"crossref","first-page":"6923213","DOI":"10.1155\/2018\/6923213","article-title":"TNFAIP3 F127C coding variation in Greek primary sjogren's syndrome patients","volume":"2018","author":"Nezos","year":"2018","journal-title":"Journal of immunology research"},{"key":"10.1016\/j.jaut.2019.102317_bib101","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.38308","article-title":"Contribution of functional LILRA3, but not nonfunctional LILRA3, to sex bias in susceptibility and severity of anti-citrullinated protein antibody-positive rheumatoid arthritis","volume":"66","author":"Du","year":"2014","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.jaut.2019.102317_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134414","article-title":"Influence of the LILRA3 deletion on multiple sclerosis risk: original data and meta-analysis","volume":"10","author":"Ortiz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102317_bib103","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/annrheumdis-2019-eular.6054","article-title":"Association of LILRA3 gene with lymphomagenesis risk in young SS patients","volume":"78","author":"Argyriou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib104","doi-asserted-by":"crossref","first-page":"7682827","DOI":"10.1155\/2019\/7682827","article-title":"STAT4, TRAF3IP2, IL10, and HCP5 polymorphisms in sjogren's syndrome: association with disease susceptibility and clinical aspects","volume":"2019","author":"Colafrancesco","year":"2019","journal-title":"Journal of immunology research"},{"key":"10.1016\/j.jaut.2019.102317_bib105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2019.102317_bib106","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/gene.2010.73","article-title":"Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort","volume":"12","author":"Namjou","year":"2011","journal-title":"Genes Immun."},{"key":"10.1016\/j.jaut.2019.102317_bib107","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.4049\/jimmunol.1401334","article-title":"Phenotypic variation in Aicardi-Goutieres syndrome explained by cell-specific IFN-stimulated gene response and cytokine release","volume":"194","author":"Cuadrado","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2019.102317_bib108","series-title":"TREX1 Variants in Sjogren's Syndrome Related Lymphomagenesis","first-page":"154781","author":"Nezos","year":"2019"},{"key":"10.1016\/j.jaut.2019.102317_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003137","article-title":"Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity","volume":"9","author":"De","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.jaut.2019.102317_bib110","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2017-212639","article-title":"Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjogren's syndrome","volume":"77","author":"Kapsogeorgou","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib111","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaut.2017.10.004","article-title":"Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: role of methylating enzymes","volume":"88","author":"Mavragani","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102317_bib112","doi-asserted-by":"crossref","first-page":"7354","DOI":"10.1038\/s41598-017-07347-w","article-title":"MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome","volume":"7","author":"Fragkioudaki","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2019.102317_bib113","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/978-94-007-4525-4_26","article-title":"DNA methylation and cancer","volume":"61","author":"Gokul","year":"2013","journal-title":"Sub-cellular biochemistry"},{"key":"10.1016\/j.jaut.2019.102317_bib114","doi-asserted-by":"crossref","first-page":"754825","DOI":"10.1155\/2015\/754825","article-title":"Contribution of genetic factors to sjogren's syndrome and sjogren's syndrome related lymphomagenesis","volume":"2015","author":"Nezos","year":"2015","journal-title":"Journal of immunology research"},{"issue":"Suppl 2","key":"10.1016\/j.jaut.2019.102317_bib115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/annrheumdis-2019-eular.5514","article-title":"Serum thymic stromal lymphopoietin (TSLP) as a biomarker of B-cell lymphoproliferation in sjogren's syndrome","volume":"78","author":"Gandolfo","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102317_bib116","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/acr.22720","article-title":"Fatigue in primary sjogren's syndrome: clinical, laboratory, psychometric, and biologic associations","volume":"68","author":"Karageorgas","year":"2016","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2019.102317_bib117","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.24311","article-title":"Prevalence, severity, and predictors of fatigue in subjects with primary Sjogren's syndrome","volume":"59","author":"Segal","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102317_bib118","article-title":"Pain and fatigue in primary Sjogren\u2019s syndrome","author":"Omdal","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102317_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172056","article-title":"It's more than dryness and fatigue: the patient perspective on health-related quality of life in Primary Sjogren's Syndrome - a qualitative study","volume":"12","author":"Lackner","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102317_bib120","doi-asserted-by":"crossref","first-page":"391984","DOI":"10.1155\/2013\/391984","article-title":"Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases","volume":"2013","author":"Murakami","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jaut.2019.102317_bib121","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12974-019-1502-8","article-title":"Interleukin-1-related activity and hypocretin-1 in cerebrospinal fluid contribute to fatigue in primary Sjogren's syndrome","volume":"16","author":"Bardsen","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jaut.2019.102317_bib122","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/annrheumdis-2019-eular.7024","article-title":"Association between single nucleotide polymorphisms (SNPS) of the BAFF gene and fatigue in primary Sjogren's syndrome","volume":"78","author":"Flessa","year":"2019","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119305037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119305037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:24:06Z","timestamp":1760257446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841119305037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":122,"alternative-id":["S0896841119305037"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102317","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic contributors and soluble mediators in prediction of autoimmune comorbidity","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102317"}}